{
    "data": [
        {
            "id": "4312287",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-13T01:08:51-05:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Allergan: Don't Ring The Bell Yet",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "247025",
                            "type": "sentiment"
                        },
                        {
                            "id": "247026",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4312287-allergan-dont-ring-bell-yet"
            }
        },
        {
            "id": "4309824",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-30T06:08:44-05:00",
                "isLockedPro": false,
                "commentCount": 44,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Assessing If AbbVie's Dividend Is Safe",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23407",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "243663",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4309824-assessing-abbvies-dividend-is-safe"
            }
        },
        {
            "id": "4309633",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-28T06:53:45-05:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Still Yields Over 5%",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "243642",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4309633-abbvie-still-yields-over-5-percent"
            }
        },
        {
            "id": "4309295",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-26T15:45:09-05:00",
                "isLockedPro": false,
                "commentCount": 79,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why AbbVie Might Fall After The Mega-Merger With Allergan",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "243703",
                            "type": "sentiment"
                        },
                        {
                            "id": "243711",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4309295-why-abbvie-might-fall-after-mega-merger-allergan"
            }
        },
        {
            "id": "4308909",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-25T09:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 65,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Is The First Addition To The Motorhome Retirement 72T Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104843",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "243091",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4308909-abbvie-is-first-addition-to-motorhome-retirement-72t-portfolio"
            }
        },
        {
            "id": "4307408",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-18T09:10:37-05:00",
                "isLockedPro": false,
                "commentCount": 72,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What's $30B Among Friends?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25321",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "81844",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4307408-30b-among-friends"
            }
        },
        {
            "id": "4305904",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-12T15:38:12-05:00",
                "isLockedPro": false,
                "commentCount": 109,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Amazing Dividend, Attractive Valuation, Uncertain Future",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "80575",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4305904-abbvie-amazing-dividend-attractive-valuation-uncertain-future"
            }
        },
        {
            "id": "4304464",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-08T12:32:57-05:00",
                "isLockedPro": false,
                "commentCount": 121,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Our Top Dividend Stock To Buy Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23407",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "79529",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4304464-abbvie-top-dividend-stock-to-buy-now"
            }
        },
        {
            "id": "4300045",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-29T15:27:00-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie And Roche Continue The Battle For The Leadership In AML And CLL Markets",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104870",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "70070",
                            "type": "sentiment"
                        },
                        {
                            "id": "70069",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4300045-abbvie-and-roche-continue-battle-for-leadership-in-aml-and-cll-markets"
            }
        },
        {
            "id": "4299978",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-29T14:28:30-04:00",
                "isLockedPro": false,
                "commentCount": 50,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Still Positioned To Deliver Alpha Over The Next Decade",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "67545",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4299978-abbvie-still-positioned-to-deliver-alpha-over-next-decade"
            }
        },
        {
            "id": "4295290",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-06T17:01:32-04:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie-Allergan Merger - Don't Worry About Debt, AbbVie Is Still A Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105284",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "72298",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4295290-abbvie-allergan-merger-dont-worry-debt-abbvie-is-still-buy"
            }
        },
        {
            "id": "4294560",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-02T10:12:23-04:00",
                "isLockedPro": false,
                "commentCount": 583,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why I Have 28% Of My Retirement Portfolio Invested In These 3 High-Yield Blue Chips",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "71586",
                            "type": "sentiment"
                        },
                        {
                            "id": "71587",
                            "type": "sentiment"
                        },
                        {
                            "id": "71588",
                            "type": "sentiment"
                        },
                        {
                            "id": "71589",
                            "type": "sentiment"
                        },
                        {
                            "id": "71590",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4294560-why-i-28-percent-of-retirement-portfolio-invested-in-3-high-yield-blue-chips"
            }
        },
        {
            "id": "4293484",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-25T13:00:05-04:00",
                "isLockedPro": false,
                "commentCount": 47,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie And Allergan: Huge Debt Levels And Doubtful Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "65033",
                            "type": "sentiment"
                        },
                        {
                            "id": "65034",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4293484-abbvie-and-allergan-huge-debt-levels-and-doubtful-growth"
            }
        },
        {
            "id": "4293232",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-24T10:04:01-04:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: The Allergan Merger Is Poised To Be More Accretive Than The Market Realizes",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105446",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "68331",
                            "type": "sentiment"
                        },
                        {
                            "id": "68332",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4293232-abbvie-allergan-merger-is-poised-to-be-accretive-market-realizes"
            }
        },
        {
            "id": "4292892",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-23T08:15:00-04:00",
                "isLockedPro": false,
                "commentCount": 73,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Is One Of The Best High-Yield Stocks You Can Buy Right Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "68830",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4292892-abbvie-is-one-of-best-high-yield-stocks-you-can-buy-right-now"
            }
        },
        {
            "id": "4290681",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-10T09:15:05-04:00",
                "isLockedPro": false,
                "commentCount": 96,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: The 6.5% Yield Window Won't Stay Open Much Longer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101935",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "64694",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4290681-abbvie-6_5-percent-yield-window-wont-stay-open-much-longer"
            }
        },
        {
            "id": "4289843",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-05T11:53:43-04:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Allergan: Why I Like This AbbVie Target",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "65129",
                            "type": "sentiment"
                        },
                        {
                            "id": "65130",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4289843-allergan-why-i-like-this-abbvie-target"
            }
        },
        {
            "id": "4289440",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-03T19:57:58-04:00",
                "isLockedPro": false,
                "commentCount": 131,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Even Better Dividend Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "64721",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4289440-abbvie-even-better-dividend-now"
            }
        },
        {
            "id": "4288378",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-28T08:18:14-04:00",
                "isLockedPro": false,
                "commentCount": 41,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Shareholders Can Earn 17% On Excess Cash Through Merger Arbitrage",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105284",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "62868",
                            "type": "sentiment"
                        },
                        {
                            "id": "62869",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4288378-abbvie-shareholders-can-earn-17-percent-on-excess-cash-through-merger-arbitrage"
            }
        },
        {
            "id": "4288332",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-28T02:35:33-04:00",
                "isLockedPro": false,
                "commentCount": 230,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons AbbVie Is One Of The Best High-Yield Blue Chips For Times Like These",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "63164",
                            "type": "sentiment"
                        },
                        {
                            "id": "63165",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4288332-3-reasons-abbvie-is-one-of-best-high-yield-blue-chips-for-times-like"
            }
        },
        {
            "id": "4287105",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-21T12:00:14-04:00",
                "isLockedPro": false,
                "commentCount": 122,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Low P/E Multiple, Solid Dividend And Favorable Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71565",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "61629",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4287105-abbvie-low-p-e-multiple-solid-dividend-and-favorable-growth"
            }
        },
        {
            "id": "4286448",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-18T06:53:50-04:00",
                "isLockedPro": false,
                "commentCount": 100,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie's FDA Approval For RINVOQ Sets Up First Phase Of Deployment Plan To Counter Humira Issue",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "60839",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4286448-abbvies-fda-approval-for-rinvoq-sets-up-first-phase-of-deployment-plan-to-counter-humira"
            }
        },
        {
            "id": "4284856",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-12T12:08:50-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Future Of HCV Market Duopoly",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104870",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "59174",
                            "type": "sentiment"
                        },
                        {
                            "id": "59175",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4284856-future-of-hcv-market-duopoly"
            }
        },
        {
            "id": "4283110",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-08T08:45:08-04:00",
                "isLockedPro": false,
                "commentCount": 260,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Testing Our Capacity To Suffer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101935",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "55961",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4283110-abbvie-testing-capacity-to-suffer"
            }
        },
        {
            "id": "4282337",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-06T20:11:37-04:00",
                "isLockedPro": false,
                "commentCount": 67,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Will Be Formidable After Acquiring Allergan",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "57600",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4282337-abbvie-will-be-formidable-after-acquiring-allergan"
            }
        },
        {
            "id": "4281464",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-04T15:26:49-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Portfolio: Halftime Report",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23998",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "57285",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4281464-abbvie-portfolio-halftime-report"
            }
        },
        {
            "id": "4278534",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-29T04:09:54-04:00",
                "isLockedPro": false,
                "commentCount": 179,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why AbbVie Wants Allergan; How That Changes It As A Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "55636",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4278534-why-abbvie-wants-allergan-how-changes-stock"
            }
        },
        {
            "id": "4276917",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-24T03:15:00-04:00",
                "isLockedPro": false,
                "commentCount": 113,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Another Disastrous Pharma Merger: AbbVie And Allergan",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104227",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "54259",
                            "type": "sentiment"
                        },
                        {
                            "id": "54260",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4276917-another-disastrous-pharma-merger-abbvie-and-allergan"
            }
        },
        {
            "id": "4274785",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-13T05:43:45-04:00",
                "isLockedPro": false,
                "commentCount": 74,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "If You Like AbbVie, You Should Be Buying Allergan",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104023",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "51953",
                            "type": "sentiment"
                        },
                        {
                            "id": "51954",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4274785-you-like-abbvie-you-should-be-buying-allergan"
            }
        },
        {
            "id": "4274274",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-10T12:03:46-04:00",
                "isLockedPro": false,
                "commentCount": 142,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Things Investors Need To Know About AbbVie's Future",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "51156",
                            "type": "sentiment"
                        },
                        {
                            "id": "51157",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4274274-3-things-investors-need-to-know-abbvies-future"
            }
        },
        {
            "id": "4274213",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-10T08:45:00-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Gets Even More Complicated With Allergan",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101935",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "50527",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4274213-abbvie-gets-even-complicated-allergan"
            }
        },
        {
            "id": "4274192",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-10T02:12:56-04:00",
                "isLockedPro": false,
                "commentCount": 53,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "I Increased My AbbVie Position, You Should As Well",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "50148",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4274192-i-increased-abbvie-position-you-should-well"
            }
        },
        {
            "id": "4274082",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-09T12:24:19-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie-Allergan: A Boring But Prudent Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "37741",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "50675",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4274082-abbvie-allergan-boring-prudent-deal"
            }
        },
        {
            "id": "4273784",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-08T09:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Federal Realty Is Added To The Grade 'A' Retirement Portfolio Waitlist And AbbVie Is Not",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104843",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "50678",
                            "type": "sentiment"
                        },
                        {
                            "id": "50419",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4273784-federal-realty-is-added-to-grade-a-retirement-portfolio-waitlist-and-abbvie-is-not"
            }
        },
        {
            "id": "4273352",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-03T14:09:27-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie's Buy Of Allergan Is A Defensive Play, A Necessary One To Maintain Progress",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "49666",
                            "type": "sentiment"
                        },
                        {
                            "id": "49896",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4273352-abbvies-buy-of-allergan-is-defensive-play-necessary-one-to-maintain-progress"
            }
        },
        {
            "id": "4273231",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-03T00:41:22-04:00",
                "isLockedPro": false,
                "commentCount": 89,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Recent Purchase: AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "49450",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4273231-recent-purchase-abbvie"
            }
        },
        {
            "id": "4272872",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-30T23:09:20-04:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buying AbbVie Was A No-Brainer After This Analysis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103182",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "48682",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272872-buying-abbvie-was-no-brainer-after-this-analysis"
            }
        },
        {
            "id": "4272847",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-30T17:40:00-04:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie And Gilead - 2 Different Strategies To Improve Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105284",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "48605",
                            "type": "sentiment"
                        },
                        {
                            "id": "48606",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272847-abbvie-and-gilead-2-different-strategies-to-improve-growth"
            }
        },
        {
            "id": "4272752",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-29T01:04:35-04:00",
                "isLockedPro": false,
                "commentCount": 88,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merger Math: Allergan + AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104023",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "48551",
                            "type": "sentiment"
                        },
                        {
                            "id": "48552",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272752-merger-math-allergan-abbvie"
            }
        },
        {
            "id": "4272739",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-28T17:50:28-04:00",
                "isLockedPro": false,
                "commentCount": 61,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Allergan Is Not The Solution",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "48655",
                            "type": "sentiment"
                        },
                        {
                            "id": "48810",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272739-abbvie-allergan-is-not-solution"
            }
        },
        {
            "id": "4272662",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-28T11:35:41-04:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie And Allergan - Take Advantage Of AbbVie's Share Price Drop",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "48339",
                            "type": "sentiment"
                        },
                        {
                            "id": "48340",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272662-abbvie-and-allergan-take-advantage-of-abbvies-share-price-drop"
            }
        },
        {
            "id": "4272577",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-27T21:39:36-04:00",
                "isLockedPro": false,
                "commentCount": 57,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: $63 Billion Allergan Acquisition Just What The Doctor Ordered",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "48158",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272577-abbvie-63-billion-allergan-acquisition-just-what-doctor-ordered"
            }
        },
        {
            "id": "4272550",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-27T17:17:38-04:00",
                "isLockedPro": false,
                "commentCount": 124,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Dividend Is Safe",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "48330",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272550-abbvie-dividend-is-safe"
            }
        },
        {
            "id": "4272398",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-27T08:34:33-04:00",
                "isLockedPro": false,
                "commentCount": 119,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie, Allergan, Ugh",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "48395",
                            "type": "sentiment"
                        },
                        {
                            "id": "48396",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272398-abbvie-allergan-ugh"
            }
        },
        {
            "id": "4272290",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-26T15:43:05-04:00",
                "isLockedPro": false,
                "commentCount": 122,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What To Do With AbbVie After The Allergan Bid",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "48118",
                            "type": "sentiment"
                        },
                        {
                            "id": "48119",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272290-what-to-abbvie-after-allergan-bid"
            }
        },
        {
            "id": "4272262",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-26T14:51:07-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Shares Stumble",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23998",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "48055",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272262-abbvie-shares-stumble"
            }
        },
        {
            "id": "4272162",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-26T07:05:42-04:00",
                "isLockedPro": false,
                "commentCount": 82,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What To Make Of AbbVie Buying Allergan",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "38311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "47999",
                            "type": "sentiment"
                        },
                        {
                            "id": "48071",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272162-what-to-make-of-abbvie-buying-allergan"
            }
        },
        {
            "id": "4272160",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-26T06:58:51-04:00",
                "isLockedPro": false,
                "commentCount": 263,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Has It All: Growth, Dividend Growth And Compelling Valuation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23179",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "47949",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272160-abbvie-all-growth-dividend-growth-and-compelling-valuation"
            }
        },
        {
            "id": "4272096",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-25T18:57:25-04:00",
                "isLockedPro": false,
                "commentCount": 58,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What To Do With Allergan After AbbVie Bid",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "47851",
                            "type": "sentiment"
                        },
                        {
                            "id": "47852",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272096-what-to-allergan-after-abbvie-bid"
            }
        },
        {
            "id": "4271585",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-21T19:22:39-04:00",
                "isLockedPro": false,
                "commentCount": 93,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie SWOT Analysis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21798",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "46106",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4271585-abbvie-swot-analysis"
            }
        },
        {
            "id": "4268363",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-05T06:03:50-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb And AbbVie: Pharma Dividend Opportunities With Large Margins Of Safety",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105006",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "42907",
                            "type": "sentiment"
                        },
                        {
                            "id": "42908",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4268363-bristol-myers-squibb-and-abbvie-pharma-dividend-opportunities-large-margins-of-safety"
            }
        },
        {
            "id": "4268084",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-03T20:06:35-04:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Multiple Blockbusters To Treat Humira's Revenue Declines",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21798",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "42415",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4268084-abbvie-multiple-blockbusters-to-treat-humiras-revenue-declines"
            }
        },
        {
            "id": "4267851",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-03T01:52:51-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie's Skyrizi And Upadacitinib May Not Be Enough To Offset Humira Declines",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "78545",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "42306",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4267851-abbvies-skyrizi-and-upadacitinib-may-not-be-enough-to-offset-humira-declines"
            }
        },
        {
            "id": "4264574",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-16T10:34:16-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Grabs FDA Approval In HCV, Faces Several Risks",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "38403",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4264574-abbvie-grabs-fda-approval-in-hcv-faces-several-risks"
            }
        },
        {
            "id": "4264065",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-14T21:20:37-04:00",
                "isLockedPro": false,
                "commentCount": 76,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Is Undervalued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102764",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "38106",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4264065-abbvie-is-undervalued"
            }
        },
        {
            "id": "4259556",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-03T09:22:07-04:00",
                "isLockedPro": false,
                "commentCount": 106,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: No Reason To Throw In The Towel",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101935",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "34701",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4259556-abbvie-no-reason-to-throw-in-towel"
            }
        },
        {
            "id": "4259024",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-02T10:34:54-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Building A Bulletproof Portfolio Around AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23998",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "35078",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4259024-building-bulletproof-portfolio-around-abbvie"
            }
        },
        {
            "id": "4258202",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-30T16:54:26-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Financial Exchange Stock Talk: Dividend Sensei On AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "34663",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4258202-financial-exchange-stock-talk-dividend-sensei-on-abbvie"
            }
        },
        {
            "id": "4258042",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-30T12:34:27-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Looks To Tackle Humira Biosimilar Issue With 2 New Powerhouse Drugs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "34403",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4258042-abbvie-looks-to-tackle-humira-biosimilar-issue-2-new-powerhouse-drugs"
            }
        },
        {
            "id": "4257908",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-30T04:33:11-04:00",
                "isLockedPro": false,
                "commentCount": 58,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Value Trap? Maybe, But Here's Why It Can Revive",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "34326",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4257908-abbvie-value-trap-maybe-why-can-revive"
            }
        },
        {
            "id": "4257612",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-29T07:17:02-04:00",
                "isLockedPro": false,
                "commentCount": 195,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Is A Classic Buffett Style Blue Chip Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "33704",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4257612-abbvie-is-classic-buffett-style-blue-chip-buy"
            }
        },
        {
            "id": "4255865",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-23T06:16:40-04:00",
                "isLockedPro": false,
                "commentCount": 72,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Trapping AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103219",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "32362",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4255865-trapping-abbvie"
            }
        },
        {
            "id": "4255683",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-22T11:04:19-04:00",
                "isLockedPro": false,
                "commentCount": 174,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: This Dividend Aristocrat Is Set To Crush The Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "31912",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4255683-abbvie-this-dividend-aristocrat-is-set-to-crush-market"
            }
        },
        {
            "id": "4254083",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-11T19:48:41-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie's Psoriasis Drug Approved For Japan, But The Main Event Is Yet To Come",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "30298",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4254083-abbvies-psoriasis-drug-approved-for-japan-main-event-is-yet-to-come"
            }
        },
        {
            "id": "4253644",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-09T20:09:45-04:00",
                "isLockedPro": false,
                "commentCount": 57,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: This 5% Yielding Dividend Aristocrat Is Undervalued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "29585",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4253644-abbvie-this-5-percent-yielding-dividend-aristocrat-is-undervalued"
            }
        },
        {
            "id": "4253348",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-08T13:21:04-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Worst Case Scenario For AbbVie Is Not That Bad",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "37741",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "29185",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4253348-worst-case-scenario-for-abbvie-is-not-bad"
            }
        },
        {
            "id": "4251639",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-28T16:28:25-04:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie And Spirit Realty: 2 Undervalued, High-Yield Picks For Your Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "26527",
                            "type": "sentiment"
                        },
                        {
                            "id": "26528",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4251639-abbvie-and-spirit-realty-2-undervalued-high-yield-picks-for-your-portfolio"
            }
        },
        {
            "id": "4250342",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-21T15:07:04-04:00",
                "isLockedPro": false,
                "commentCount": 73,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Not A Swan, But A Steal At Its Current Price",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "25146",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4250342-abbvie-not-swan-steal-current-price"
            }
        },
        {
            "id": "4249896",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-20T09:15:08-04:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What Investors Are Missing About AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101935",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "24374",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4249896-what-investors-are-missing-abbvie"
            }
        },
        {
            "id": "4249529",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-18T14:52:43-04:00",
                "isLockedPro": false,
                "commentCount": 247,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "5 Reasons AbbVie Is My Biggest Holding",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "23865",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4249529-5-reasons-abbvie-is-biggest-holding"
            }
        },
        {
            "id": "4241706",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-17T08:01:42-05:00",
                "isLockedPro": false,
                "commentCount": 94,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bert's Recent Purchase - AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "73495",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4241706-berts-recent-purchase-abbvie"
            }
        },
        {
            "id": "4240912",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-14T07:23:29-05:00",
                "isLockedPro": false,
                "commentCount": 83,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Is Too Risky Right Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32121",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4240912-abbvie-is-too-risky-right-now"
            }
        },
        {
            "id": "4240000",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-11T17:32:03-05:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Suffers Market Loss For Humira In Europe, But The U.S. Is A Different Story",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "7894",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4240000-abbvie-suffers-market-loss-for-humira-in-europe-u-s-is-different-story"
            }
        },
        {
            "id": "4239466",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-08T12:47:17-05:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "After Humira: AbbVie's Upa Vs. Gilead's Filgo",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "6783",
                            "type": "sentiment"
                        },
                        {
                            "id": "6784",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4239466-after-humira-abbvies-upa-vs-gileads-filgo"
            }
        },
        {
            "id": "4236920",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-31T01:58:45-05:00",
                "isLockedPro": false,
                "commentCount": 63,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie's Existential Tests Are Upon It",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "6147",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4236920-abbvies-existential-tests-are-upon"
            }
        },
        {
            "id": "4236108",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-28T18:33:51-05:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Tough 2019 Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "6306",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4236108-abbvie-tough-2019-ahead"
            }
        },
        {
            "id": "4235895",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-28T04:45:11-05:00",
                "isLockedPro": false,
                "commentCount": 330,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons I Just Tripled Down On AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "6152",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4235895-3-reasons-i-just-tripled-down-on-abbvie"
            }
        },
        {
            "id": "4235824",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-27T10:22:54-05:00",
                "isLockedPro": false,
                "commentCount": 107,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Not Driving Via The Rearview Mirror",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "6097",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4235824-abbvie-not-driving-via-rearview-mirror"
            }
        },
        {
            "id": "4235759",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-26T03:53:18-05:00",
                "isLockedPro": false,
                "commentCount": 132,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy AbbVie's Big Drop",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101935",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "6066",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4235759-buy-abbvies-big-drop"
            }
        },
        {
            "id": "4234823",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-22T17:24:00-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Enanta And EDP-305 In NASH: What's In It For AbbVie?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104202",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "5548",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4234823-enanta-and-edpminus-305-in-nash-in-for-abbvie"
            }
        }
    ]
}